From Portfolio to Pipeline: How Medtech Marketers Turn Buyer Insight Into Commercial Momentum

DeviceTalks Minnesota Panel Discussion

Saul Marquez, CEO, Outcomes Rocket | Featuring Caitlin Mayer, Sr. Director, US Marketing, Medtronic Acute Care & Monitoring

In medtech, marketing has never been harder.

Buying cycles are long. Clinical decisions are multi-stakeholder. Product portfolios compete for attention inside the same accounts, often against each other. And every marketing leader we talk to is being asked the same question by their CEO: how do we do more with the same team, prove contribution, and sustain momentum beyond the next budget cycle?

This is the conversation we're taking to the DeviceTalks Minnesota stage with Caitlin Mayer, Senior Director of US Marketing at Medtronic Acute Care & Monitoring. She runs marketing for one of the most complex portfolios in the industry, and she's one of the sharpest thinkers we know on how medtech marketing can drive commercial outcomes, not just awareness.

Here's a preview of what we're unpacking, and what we think every medtech marketing leader should be wrestling with right now.

The shift from feature-led to outcomes-led positioning

Most medtech marketing still leads with features: specs, clearances, platform capabilities. It's the default, and it's killing pipeline velocity.

The reason is structural. A medtech buying committee includes clinicians, value analysis leaders, supply chain, and the C-suite. Each stakeholder cares about a different outcome. When marketing leads with features, it forces every stakeholder to translate those features into their own value framework, length of stay, cost per case, adverse events, operational complexity, on their own. That translation work happens in silence, in side conversations, without marketing in the room. Some stakeholders do the math and advocate internally. Most don't, and the deal stalls.

Outcomes-led positioning does the translation upfront. It says: here is the clinical outcome, here is the economic outcome, here is the operational outcome, and here is the proof. Each stakeholder gets handed the argument they need to advocate internally. The result is faster alignment inside the account and more predictable commercial momentum.

The teams that make this shift don't just rewrite their messaging. They rebuild how marketing works with clinical affairs, HEOR, and sales, because outcomes-led positioning requires evidence that lives across those functions.

The role of voice-of-customer research in a portfolio strategy

You cannot build outcomes-led positioning on internal assumptions. You need the buyer's actual language, priorities, and objections.

This is where voice-of-customer research earns its keep. In medtech specifically, VoC surfaces the tensions inside buying committees that marketing is usually blind to. The clinician champion who's excited about a new technology, but worried about the learning curve. The value analysis lead who needs the economic model for the next committee meeting, not next quarter. The supply chain lead whose real concern is implementation risk, not list price.

When marketing has that level of insight, portfolio decisions get sharper. You know which product in the portfolio has the strongest pull in which segment, which messaging lands with which persona, and where the real objections sit. Without it, you're guessing.

The best VoC programs aren't one-time projects. They're continuous. They feed portfolio prioritization, launch planning, competitive positioning, and sales enablement on an ongoing basis. That's the bar, and most teams are operating well below it.

Aligning clinical, commercial, and marketing around a shared narrative

The internal alignment problem kills more medtech pipeline than any external competitor.

A product launches with a clinical narrative built by medical affairs, a commercial pitch built by the sales leader, and a marketing campaign built by the marketing team. The three versions overlap in places and contradict in others. The buying committee picks up on the inconsistency immediately, because their own internal reviewers are going to test the claims.

What changes this is a shared narrative: one story that clinical, commercial, and marketing all tell in their own voice, but with the same core claim, the same outcomes, and the same proof points. Building it is political work as much as strategic work. It requires marketing leaders to earn the right to facilitate the conversation, which means showing up with buyer insight that the clinical and commercial leaders don't already have.

When the shared narrative is in place, pipeline velocity changes because the account is hearing one consistent story from every touchpoint. When it isn't, every deal gets slower and every launch gets more expensive.

When to build internally vs. when to bring in an external partner

This is the question we get asked most, and the one most marketing leaders avoid answering clearly.

Keep work internal when it requires deep institutional knowledge, ongoing stakeholder management, or tight integration with clinical and regulatory teams. That work doesn't travel well to an outside agency, and trying to outsource it usually backfires.

Bring in an external partner when the work requires specialized research capability your team doesn't have (rigorous VoC, competitive intelligence, market sizing), when internal capacity is the bottleneck to launching on time, or when an outside perspective is needed to challenge assumptions that have calcified internally.

The signal it's time for external help is usually a repeating gap between marketing ambition and marketing output. The team knows what to do. They just can't get it done inside the current budget cycle. That's a capacity problem or a capability problem, not a strategy problem, and it's solvable.

What the best medtech marketing leaders are doing differently

The pattern across the teams we work with that are outperforming comes down to four things:

They treat positioning as an ongoing system, not a launch deliverable. They build voice-of-customer research into the operating cadence of the function. They invest in the internal alignment work that makes a shared narrative possible. And they're clear-eyed about where their team ends and where a partner begins.

None of this is glamorous. All of it is learnable. And it's what separates the marketing leaders who get the next budget cycle from the ones who don't.

Join us at DeviceTalks Minnesota

Caitlin and Saul are unpacking all of this live at DeviceTalks Minnesota, with real examples from inside Medtronic Acute Care & Monitoring and from Outcomes Rocket's 2026 State of B2B GTM Strategy research (511 marketing and commercial leaders across the US and UK).

If you're a medtech marketing leader wrestling with any of this, come find us at the session. And if you can't make it in person we'll share the video of our panel as soon as it's live on this blog.

‍